Physician profile
Matthew Griffith
NPI 1871223982
$1,200.07
in general payments reported to CMS, 2019-2025
10 companies · $637 in 2025
The $637 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $169 · 2024: $394 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $331.60 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $281.33 | 2025 | |
| Mallinckrodt Hospital Products INC. | $146.10 | 2024 | Acthar |
| Alcon Vision LLC | $130.72 | 2023-2025 | Clareon Panoptix Pro, Rocklatan, Clareon |
| Sun Pharmaceutical Industries INC. | $124.71 | 2023 | Cequa |
| Bausch & Lomb Americas INC. | $75.56 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Thea Pharma INC. | $43.60 | 2024-2025 | Iyuzeh |
| Abbvie INC. | $25.16 | 2024 | |
| Ani Pharmaceuticals, INC. | $24.80 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $16.49 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.